These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

315 related articles for article (PubMed ID: 15791568)

  • 21. Co-expression of receptor tyrosine kinases in esophageal adenocarcinoma and squamous cell cancer.
    Gockel I; Moehler M; Frerichs K; Drescher D; Trinh TT; Duenschede F; Borschitz T; Schimanski K; Biesterfeld S; Herzer K; Galle PR; Lang H; Junginger T; Schimanski CC
    Oncol Rep; 2008 Oct; 20(4):845-50. PubMed ID: 18813825
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Tyrosine kinase expression in pulmonary metastases and paired primary tumors.
    Muehling BM; Toelkes S; Schelzig H; Barth TF; Sunder-Plassmann L
    Interact Cardiovasc Thorac Surg; 2010 Feb; 10(2):228-31. PubMed ID: 19948538
    [TBL] [Abstract][Full Text] [Related]  

  • 23. KIT and platelet-derived growth factor receptor alpha tyrosine kinase gene mutations and KIT amplifications in human solid tumors.
    Sihto H; Sarlomo-Rikala M; Tynninen O; Tanner M; Andersson LC; Franssila K; Nupponen NN; Joensuu H
    J Clin Oncol; 2005 Jan; 23(1):49-57. PubMed ID: 15545668
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evidence for activation of KIT, PDGFRalpha, and PDGFRbeta receptors in the Ewing sarcoma family of tumors.
    Bozzi F; Tamborini E; Negri T; Pastore E; Ferrari A; Luksch R; Casanova M; Pierotti MA; Bellani FF; Pilotti S
    Cancer; 2007 Apr; 109(8):1638-45. PubMed ID: 17342771
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression and mutational analyses of KIT and PDGFR-alpha in sarcomatoid renal cell carcinoma.
    Petit A; Castillo M; Gaspa A; Colomer D; Garcia de Albéniz X; Moreno C; Camós M; Mellado B; Mallofré C
    Histopathology; 2009 Aug; 55(2):230-2. PubMed ID: 19694830
    [No Abstract]   [Full Text] [Related]  

  • 26. Coexpression of the c-kit and stem cell factor genes in breast carcinomas.
    Hines SJ; Organ C; Kornstein MJ; Krystal GW
    Cell Growth Differ; 1995 Jun; 6(6):769-79. PubMed ID: 7545433
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Amplification of genes encoding KIT, PDGFRalpha and VEGFR2 receptor tyrosine kinases is frequent in glioblastoma multiforme.
    Joensuu H; Puputti M; Sihto H; Tynninen O; Nupponen NN
    J Pathol; 2005 Oct; 207(2):224-31. PubMed ID: 16021678
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors.
    Inoue M; Kyo S; Fujita M; Enomoto T; Kondoh G
    Cancer Res; 1994 Jun; 54(11):3049-53. PubMed ID: 7514496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Analysis of potential receptor tyrosine kinase targets in intimal and mural sarcomas.
    Tamborini E; Casieri P; Miselli F; Orsenigo M; Negri T; Piacenza C; Stacchiotti S; Gronchi A; Pastorino U; Pierotti MA; Pilotti S
    J Pathol; 2007 Jun; 212(2):227-35. PubMed ID: 17471466
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Mutation and expression of PDGFRA and KIT in malignant peripheral nerve sheath tumors, and its implications for imatinib sensitivity.
    Holtkamp N; Okuducu AF; Mucha J; Afanasieva A; Hartmann C; Atallah I; Estevez-Schwarz L; Mawrin C; Friedrich RE; Mautner VF; von Deimling A
    Carcinogenesis; 2006 Mar; 27(3):664-71. PubMed ID: 16357008
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Molecular analysis of PDGFRA and PDGFRB genes by rapid single-strand conformation polymorphism (SSCP) in patients with core-binding factor leukaemias with KIT or FLT3 mutation.
    Trojani A; Ripamonti CB; Penco S; Beghini A; Nadali G; Di Bona E; Viola A; Castagnola C; Colapietro P; Grillo G; Pezzetti L; Ravelli E; Patrosso MC; Marocchi A; Cuneo A; Ferrara F; Lazzarino M; Pizzolo G; Cairoli R; Morra E
    Anticancer Res; 2008; 28(5A):2745-51. PubMed ID: 19035305
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Expression of KIT and PDGFR is associated with a good prognosis in neuroblastoma.
    Shimada A; Hirato J; Kuroiwa M; Kikuchi A; Hanada R; Wakai K; Hayashi Y
    Pediatr Blood Cancer; 2008 Feb; 50(2):213-7. PubMed ID: 17941064
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Molecular characterization of PDGFR-alpha/PDGF-A and c-KIT/SCF in gliosarcomas.
    Reis RM; Martins A; Ribeiro SA; Basto D; Longatto-Filho A; Schmitt FC; Lopes JM
    Cell Oncol; 2005; 27(5-6):319-26. PubMed ID: 16373964
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Pleuro-pulmonary solitary fibrous tumors: a clinicopathologic, immunohistochemical, and molecular study of 88 cases confirming the prognostic value of de Perrot staging system and p53 expression, and evaluating the role of c-kit, BRAF, PDGFRs (alpha/beta), c-met, and EGFR.
    Schirosi L; Lantuejoul S; Cavazza A; Murer B; Yves Brichon P; Migaldi M; Sartori G; Sgambato A; Rossi G
    Am J Surg Pathol; 2008 Nov; 32(11):1627-42. PubMed ID: 18753943
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic targets in gastrointestinal stromal tumors].
    Wardelmann E; Schildhaus HU; Merkelbach-Bruse S; Büttner R
    Verh Dtsch Ges Pathol; 2006; 90():73-9. PubMed ID: 17867582
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression.
    Carvalho I; Milanezi F; Martins A; Reis RM; Schmitt F
    Breast Cancer Res; 2005; 7(5):R788-95. PubMed ID: 16168125
    [TBL] [Abstract][Full Text] [Related]  

  • 37. KIT and PDGFRalpha mutational analyses of mixed cell-type gastrointestinal stromal tumours.
    Wong NA; Mangwana S
    Histopathology; 2007 Dec; 51(6):758-62. PubMed ID: 18042065
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expression of platelet-derived growth factor (PDGF) in the epididymis and analysis of the epididymal development in PDGF-A, PDGF-B, and PDGF receptor beta deficient mice.
    Basciani S; Mariani S; Arizzi M; Brama M; Ricci A; Betsholtz C; Bondjers C; Ricci G; Catizone A; Galdieri M; Spera G; Gnessi L
    Biol Reprod; 2004 Jan; 70(1):168-77. PubMed ID: 14522834
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib mesylate in combination with docetaxel for the treatment of patients with advanced, platinum-resistant ovarian cancer and primary peritoneal carcinomatosis : a Hoosier Oncology Group trial.
    Matei D; Emerson RE; Schilder J; Menning N; Baldridge LA; Johnson CS; Breen T; McClean J; Stephens D; Whalen C; Sutton G
    Cancer; 2008 Aug; 113(4):723-32. PubMed ID: 18618737
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Gleevec (STI-571) inhibits lung cancer cell growth (A549) and potentiates the cisplatin effect in vitro.
    Zhang P; Gao WY; Turner S; Ducatman BS
    Mol Cancer; 2003 Jan; 2():1. PubMed ID: 12537587
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.